glp 1 off label use GLP-1 medications are not approved by the Food and Drug Administration to treat polyendocrine metabolic ovarian syndrome (PMOS), the condition renamed from polycystic ovary syndrome in 2026. Because the is off-label Beyond the Scale Ep. 4:

So the cheapest options in the category are some of the most protective, and the priciest are the ones you may have to argue your insurance into

The global respective SURMOUNT study program comprises four randomized controlled trials with a study duration of at least 72 weeks using the tirzepatide doses of 10 and 15 mg in the studies SURMOUNT-2 to SURMOUNT-4 and all three doses, including the 5-mg dose in SURMOUNT-1 (8285)

That's months of progressive overload

Weight loss typically totals 40-60 lb through week 24 for those starting significantly overweight

& Huang, W

The digital storytelling approach also enables interactivity